Development and Validation of Novel UPLC-MS/MS Method for the Analysis of Macitentan in Pharmaceutical Formulations

ALBAYRAK M., ATİLA A.

CURRENT PHARMACEUTICAL ANALYSIS, vol.15, no.5, pp.554-559, 2019 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 5
  • Publication Date: 2019
  • Doi Number: 10.2174/1573412915666190314142531
  • Journal Name: CURRENT PHARMACEUTICAL ANALYSIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.554-559
  • Keywords: Macitentan, pulmonary arterial hypertension, UPLC-MS/MS, validation, pharmaceutical formulations, specificity, ENDOTHELIN RECEPTOR ANTAGONIST, PHARMACOKINETICS
  • Ataturk University Affiliated: Yes

Abstract

Introduction: Macitentan is an endothelin receptor antagonist drug used in the treatment of pulmonary arterial hypertension.